Virbac S.A.

Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
  • TickerVIRP
  • ISINFR0000031577
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Fatma Ayachi
  • Nicolas Thorez
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/17/2019

...

Christophe-Raphaël Ganet

Virbac : H1 results: strong rebound – Positive signs on recovery (guidance raised) – Buy vs Neutral – target price: € 200 (vs € 185)

>H1 underlying operating profit much higher than our forecast and good momentum - H1 underlying operating profit up 48% to € 66.9m. Cash flow of € 61m vs € 33m in H1 2018. Net debt stood at € 455.5m (-€ 31.6m vs 30 June 2018 and € 61m l-f-l, excluding the impact of IFRS 16 thanks to the absence of dividends, tight control over WCR and capex). For the outlook, Virbac said that the guidance was supported by this good performance in H1: Virbac is targeting sales at the ...

Christophe-Raphaël Ganet

Virbac : Fort rebond au S1 – Signaux positifs sur la recovery (guidances relevées) – Achat vs Neutre – OC 200 € (vs 185 €)

>ROC S1 bien supérieur à notre attente et bon momentum - Le ROC S1 est en hausse de 48% à 66.9 M€. La CAF ressort à 61 M€ vs 33 M€ au S1 2018.La DN se situe à 455.5 M€ (-31.6 M€ par rapport au 30 juin 2018 et de 61 M€ lfl., hors impact IFRS16 grâce à l’absence de dividendes, un strict contrôle du BFR et des Capex.Au titre des perspectives, Virbac indique que ce bon S1 vient conforter les guidances : Virbac vise un CA dans le haut de la fourchette de 4% à 6% ...

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Fatma Ayachi
  • Nicolas Thorez
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 17/09/2019

...

Christophe-Raphaël Ganet

Virbac : H1 results: strong rebound – Positive signs on recovery (guidance raised) – Buy vs Neutral – target price: € 200 (vs € 185)

>H1 underlying operating profit much higher than our forecast and good momentum - H1 underlying operating profit up 48% to € 66.9m. Cash flow of € 61m vs € 33m in H1 2018. Net debt stood at € 455.5m (-€ 31.6m vs 30 June 2018 and € 61m l-f-l, excluding the impact of IFRS 16 thanks to the absence of dividends, tight control over WCR and capex). For the outlook, Virbac said that the guidance was supported by this good performance in H1: Virbac is targeting sales at the ...

Christophe-Raphaël Ganet

Virbac : Fort rebond au S1 – Signaux positifs sur la recovery (guidances relevées) – Achat vs Neutre – OC 200 € (vs 185 €)

>ROC S1 bien supérieur à notre attente et bon momentum - Le ROC S1 est en hausse de 48% à 66.9 M€. La CAF ressort à 61 M€ vs 33 M€ au S1 2018.La DN se situe à 455.5 M€ (-31.6 M€ par rapport au 30 juin 2018 et de 61 M€ lfl., hors impact IFRS16 grâce à l’absence de dividendes, un strict contrôle du BFR et des Capex.Au titre des perspectives, Virbac indique que ce bon S1 vient conforter les guidances : Virbac vise un CA dans le haut de la fourchette de 4% à 6% ...

Christophe-Raphaël Ganet

Virbac : Q2 2019 sales: guidance for sales and operating margin confirmed despite mixed performance. Estimates and rating unchanged

>Q2 in line– Guidance confirmed - Q2 sales came in at € 246m, i.e. +4.1% and +3% l-f-l. Growth in the quarter was driven by Asia, notably China and Japan, Latin America, thanks to brisk business in Mexico, Brazil and Chile, and finally the US. In the US, sales rose 9% (+4.6% at constant forex). Ex-Virbac sales of the Iverhart® ranges, antibiotics and dental ranges also continued to show very significant progress, offsetting the drop in the external parasiticide ranges...

Christophe-Raphaël Ganet

Virbac : CA T2 2019 : guidances de CA et de MOP, confirmées malgré du contraste. Estimations et opinion inchangées

>T2 en ligne – Guidances solidement reconduites - Le CA T2 s'est établi à 246 M€, soit +4,1% et +3% lfl. La croissance du trimestre est tirée par l’Asie notamment par la Chine et le Japon, par l’Amérique latine portée par l’activité soutenue au Mexique, au Brésil et au Chili et enfin par les États-Unis. Aux États-Unis, l’activité progresse de 9% à taux réels (+4,6% à taux de change constants). Les ventes ex-Virbac des gammes Iverhart®, antibiotiques, et dentaires cont...

Christophe-Raphaël Ganet

Virbac : L’inflexion attendue a en partie été jouée, le potentiel s’est contracté – Neutre vs Achat

Sur la base des derniers chiffres publiés, il apparaît que l’amélioration de la situation aux USA et les nombreuses initiatives du nouveau CEO ont engagé Virbac dans une trajectoire convergeant vers une MOP de 14.5%e à horizon 2023. Notre objectif de cours de 185 € suggère un potentiel plus limité à court terme (7%) : Neutre vs Achat. - >Une traversée du désert entamée en 2015 - Depuis début 2015, le marché cristallisait sur : i/ les activités USA, qui ont subi entre 2...

1 director sold

A director at Virbac sold 2,287 shares at 180.166EUR and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Fatma Ayachi
  • Nicolas Thorez
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/17/2019

...

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Fatma Ayachi
  • Nicolas Thorez
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 17/09/2019

...

Christophe-Raphaël Ganet ...
  • Emira Sagaama
  • Jeremy Garnier
  • Laurence Hofmann
  • Matthias Desmarais
  • Nicolas Thorez
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 07/17/2019

...

Christophe-Raphaël Ganet ...
  • Emira Sagaama
  • Jeremy Garnier
  • Laurence Hofmann
  • Matthias Desmarais
  • Nicolas Thorez
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 17/07/2019

...

Ahmed Ben Salem ...
  • Cecile De Coincy
  • Christophe-Raphaël Ganet
  • Florent Laroche-Joubert
  • Hana Maalej
  • Jeremy Garnier
  • Jerôme Bodin
  • Yassine Batini

ODDO BHF Small & MIDCAP MORNING NEWS - 04/12/2019

US Congress is currently discussing how best to continue securing, or even raising, funding for the country's infrastructure. Increasing the federal tax on fuel is one of the few options to receive cross-party support. This tax has not been hiked since 1993, but mindsets are changing with 39 states having already ramped up the local component of this levy in recent years. CRH and HeidelbergCement would be the main beneficiaries. - - ...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Zoetis Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Zoetis Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Zoetis Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights ...

Pauline Delecourt

Virbac 18 juin 2019

Tout d’abord, Proxinvest regrette que les rémunérations de chacun des membres du Directoire soient regroupées au sein d’une même résolution (résolution 13). En raison du regroupement des rémunérations au sein d’une même résolution, de l’absence de communication des taux de réalisation et des objectifs à atteindre et une hausse significative des bonus nous ne soutiendrons pas la résolution 13. De même, en raison de ce manque de transparence Proxinvest recommande de s'opposer aux résolutions 14 et 15, relatives aux rémunérations des dirigeants pour le nouvel exercice. En raison d’un faible tau...

Jehanne Leroy

Etude de l'AG du 23/06/2017

Proxinvest regrette principalement le manque de transparence de la communication de la société concernant les rémunérations des dirigeants mandataires sociaux. C'est, en effet, en raison de ce manque de transparence que Proxinvest recommande de s'opposer aux résolutions 8 à 12, relatives aux rémunérations des dirigeants. Proxinvest regrette par ailleurs que la société maintienne la possibilité de l'usage de ces autorisations financières en période d'offre publique, en raison de leur possible utilisation comme arme anti-OPA. Proxinvest considère en effet que les OPA sont des opportunités d'enr...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Defensive posture warranted Our outlook for global equity markets remains cautious and we expect additional weakness and consolidation, notwithstanding shorter-term countertrend rallies. Indexes throughout Europe and Asia continue their struggle to gain a firm footing, and, unsurprisingly, the same can be said of broad developed and emerging market indexes (i.e., MSCI EAFE, EM, ACWI, ACWI ex-U.S.) which are all in downtrends or have recently broken down. In light of continued global market weakness, we believe a defensive posture is warranted. In today's report we highlight various ways to ac...

Valérie GASTALDY

Short term view - VIRBAC SA : The movement can go on.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at €152.70 and €157.00. The trend would be invalidated below the support at €138.60.

Valérie GASTALDY

Analyse court terme - VIRBAC SA : Le mouvement peut se poursuivre.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 152,70 € et 157,00 €. La tendance serait invalidée sous le support à 138,60 €.

Valérie GASTALDY

Short term view - VIRBAC SA : The background trend is clearly bullish.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at €152.70 and €157.00. The trend would be invalidated below the support at €138.60.

Valérie GASTALDY

Analyse court terme - VIRBAC SA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 152,70 € et 157,00 €. La tendance serait invalidée sous le support à 138,60 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch